Avience Biomedicals IPO Listing gains
| Listing Date | June 25, 2026 |
| BSE Code | AVIENCE |
| ISIN Code | INE0V9I01017 |
| Offer Price | ₹196 to ₹208 |
| Face Value | ₹10 |
| Listing Price | ₹395.20 |
Details About Avience Biomedicals IPO
Avience Biomedicals received SEBI approval for an IPO of around ₹30.24 crore via a fresh issue. Further, Avience Biomedicals had a price band of ₹196 to ₹208 per share.
In the Avience Biomedicals IPO, 1200 shares were offered in 2 lot sizes for the retail minimum and maximum categories as well. 1800 shares were in 3 lot sizes for the S-HNI Minimum category. S-HNI maximum has 4,800 shares in 8 lot sizes. B-HNI has 5,400 shares in 9 lot sizes.
To invest in the Avience Biomedicals IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum and maximum investment of ₹2,49,600.
- S-HNI (Min): Minimum investment of ₹3,74,40.
- S-HNI Maximum: investment of ₹9,98,400.
- B-HNI Minimum: investment of ₹11,23,200.
Avience Biomedicals IPO’s Subscription Duration
The opening date of Avience Biomedicals IPO was on June 18, 2026, and the closing date was on June 22, 2026. The allotment date of the Avience Biomedicals IPO was on June 23, 2026, and the investors will receive a refund on June 24, 2026. Avience Biomedicals is set to be listed on June 25, 2026.
Funds Deployment of This Company
- The funds raised from the fresh issue will be used towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh.
- A portion of the fund wil be used for working capital requirements of the Company.
- Lastly, the remaining will go towards the General Corporate Purpose.
About Avience Biomedicals Company
Incorporated in June 2024, Avience Biomedicals is one of the leading manufacturers, suppliers, and exporters of molecular diagnostic products, testing solutions, and laboratory equipment. Its product range includes Rapid Test Kits, Biochemistry Analyzers and Reagents, Molecular Diagnostics, Hematology Analyzers, and Medical Devices.
The company’s products are distributed to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide and overseas. Avience Biomedicals Limited enhanced its product range from IVD rapid test kits to an extensive line of medical devices, including biochemistry, hematology, and serology products.
Avience Biomedicals IPO Company Financial Report
The company reported revenue of ₹45.97 crores in 2025 against ₹24.37 crores in 2024. The company reported a profit of ₹7.23 crores in 2025 against a profit of ₹2.14 crores in 2024.
